Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd and Radiotherapy for Solitary Plasmacytoma
NCT05248633Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide, dexamethasone in plasmacytoma, sponsored by Peking Union Medical College Hospital. Started Apr 2022; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
plasmacytoma
Beyond the preview
Go deeper on NCT05248633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248633.